Apexelsin® (Paclitaxel for injection,albumin-bound)has made new progress in its international expansion .It has been officially approved for marketing in the Dominican Republic, marking a further expansion of its global market access footprint in North America.

Paclitaxel for Injection (Albumin-bound) (brand name: Apexelsin®)—has received marketing approval from the Philippine Food and Drug Administration.

​Recently, GB19 Injection, independently developed by Shenzhen Kexing Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Kexing Biopharm, has officially received an Investigational New Drug (IND) approval notice from the U.S. Food and Drug Administration (FDA), allowing clinical trials to be conducted in the United States. The indication is for the treatment of cutaneous lupus erythematosus (CLE) and systemic lupus erythematosus (SLE).

Recently, a strategic cooperation and exclusive licensing agreement for Ticagrelor Tablets and Rosuvastatin Calcium Tablets across multiple European countries was signed between Kexing Biopharm and Changzhou Pharmaceutical Factory Co., Ltd. (hereinafter referred to as "Changzhou Pharmaceutical Factory"), a subsidiary of Shanghai Pharmaceutical Group.

Kexing Biopharm’s overseas commercial product Paclitaxel for Injection (Albumin Bound) (Apexelsin®), has received marketing authorization in Macao (China) and Malaysia.

Kexing Biopharm's Overseas Commercial Product——Liraglutide, the product exported in cooperation with Tonghua Dongbao Pharmaceutical, officially obtained the Good Manufacturing Practice (GMP) certificate issued by the Brazilian National Health Surveillance Agency (ANVISA).

Kexing Biopharm's innovative drug "GB19 Injection" for the treatment of systemic lupus erythematosus (SLE) received approval from National NMPA to conduct clinical trials in China. In preclinical studies, GB19 demonstrated high potency, favorable bioavailability, sustained target inhibition for over 90 days, low immunogenicity, and excellent safety profile.

Kexing Biopharm successfully secured the "Most Valuable Brand Award" for its profound brand heritage and industry influence.